Clinical Report: Creation and assessment of a new prognostic scoring system for HBV-ACLF
Overview
This study developed and validated two new prognostic scoring systems, AHF-MELD and AHN-MELD, for predicting short-term mortality in patients with HBV-associated acute-on-chronic liver failure (ACLF).
Background
Acute-on-chronic liver failure (ACLF) is characterized by high short-term mortality rates, particularly in patients with HBV infection, which is prevalent in Asia. Current prognostic models have limitations, necessitating the development of more effective tools for risk stratification and management of these patients.
Data Highlights
Score
Predictive Capacity
AHF-MELD
Stronger than MELD, MELD-sodium, CLIF-C OF, AARC
AHN-MELD
Comparable to CLIF-C ACLF, COSSH ACLF, COSSH ACLF II
Key Findings
The study included 1170 HBV-ACLF cases from a total of 5854 liver failure patients.
New scores were developed using cox regression analysis to identify predictive factors for 28-day and 90-day mortality.
AHF-MELD and AHN-MELD scores showed no significant difference between observed and predicted mortality probabilities.
High-risk groups had significantly lower survival rates compared to low-risk groups.
The new scores provided positive net benefits over a wide range of threshold probabilities.
Clinical Implications
The AHF-MELD and AHN-MELD scores may assist clinicians in predicting short-term mortality in HBV-ACLF patients.
Conclusion
The AHF-MELD and AHN-MELD scores represent tools for prognostic assessment in HBV-ACLF patients.
